🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05612906
Recruiting Observational

Renal Nerve Denervation(RDN) and Renal Function

NCT05612906 · tracked via the Priya Life Science China tracker
Sponsor
Zhengrong Huang
Phase
Observational
Started
2022-06-01
Last updated
2025-02-27

Condition(s) studied

Effects of RDN on Renal Function

Study summary

Current studies have found the efficacy of RDN in the treatment of hypertension, however, the safety of RDN in renal function is still lacking. Therefore, the investigators are aimed to study the effect of RDN on renal function.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1.18\<age≤75 years; 2.clinic blood pressure ≥ 140/90 mmHg or 24-hour ambulatory blood pressure monitoring average blood pressure ≥ 135/85 mmHg after taking 3 or more antihypertensive drugs for more than 4 weeks; 3.essential hypertension, renal parenchymal hypertension, or hypertension patients who are willing to receive RDN ; 4.who signed informed consent and were approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University. Exclusion Criteria: * pregnant women or lactating patients; * identified secondary hypertension or Pseudo hypertension; * whose renal arteries were unsuitable for ablation * obvious bleeding tendency and blood system diseases; * malignant tumors or end-stage diseases; ⑥Severe peripheral vascular disease, abdominal aortic aneurysm; ⑦A history of the acute coronary syndrome within two weeks; ⑧acute or severe systemic infection; ⑨drug or alcohol dependence or refusal to sign informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
zhengrong Huang Xiamen Fujian Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05612906 on ClinicalTrials.gov ↗ ← All trials in China